Evogene Ltd. fell 15.7% on Friday, November 6, 2026, on 405,121 shares. The headline around the move:
Evogene Ltd. (EVGN:NASDAQ) closed at $0.271 on November 6, 2026, down 15.73% on the day. The stock trades 78.8% below its 52-week high of $1.28 and 8.4% above its 52-week low of $0.250. Over the past year, it lost 76.4%. Evogene Ltd. is part of the Basic Industries sector (Agricultural Chemicals).
In 252 trading sessions since November 6, 2025, EVGN closed higher on 91 days (36%). Its best day was July 9, 2026 (+21.95%) and its worst was November 6, 2026 (-17.78%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 3 times.
Evogene Ltd. operates as a biotechnology company for the improvement of crop productivity. It operates through two segments, Evogene and Evofuel. The Evogene develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its seed trait operation develops seed traits enhancing plant yield and tolerance to abiotic stresses and biotic stresses; and ag-chemical operations develop novel herbicides and bio-stimulants. The Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. The company's products focus on various crops, including corn, soybean, wheat, rice, and cotton. It is developing seed traits for yield and abiotic stress tolerance, such as enhanced tolerance to drought, heat, and salinity; biotic stress resistance, including resistance to disease, pests, and insects; and novel herbicides. The company has strategic collaborations with various agricultural companies, such as BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 34 products in various stages of development; and a collaboration agreement with Instituto Mato-grossense do Algodao (IMAmt) for the discovery and...
Find more stocks like EVGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.